Literature DB >> 19270441

The combination of dopa-responsive parkinsonian syndrome and motor neuron disease.

Elmar Hans Pinkhardt1, Anne-Dorte Sperfeld, Hans-Jürgen Gdynia, Albert Christian Ludolph, Jan Kassubek.   

Abstract

BACKGROUND: Idiopathic Parkinson's syndrome (IPS) and motor neuron disorders (MND) are generally considered as distinct clinicopathological entities. However, cooccurrence of different neurodegenerative disorders is more frequent than would be expected. Therefore, there is an ongoing discussion whether some entities represent parts of a common spectrum. OBJECTIVE AND METHODS: We describe clinical hallmarks and treatment options in a group of 8 patients who had combined features of both a dopa-responsive parkinsonian syndrome and MND.
RESULTS: All patients exhibited a typical clinical picture of IPS, and all were treated with levodopa or other dopaminergic drugs with good clinical response. The patients also showed clinical and electrophysiological signs of upper and/or lower motor neuron degeneration. Noticeably, in contrast to well-known distinct entities like the amyotrophic lateral sclerosis-parkinsonism/ dementia complex in southwest New Guinea, we did not observe any cognitive decline during the observation period except in 1 patient.
CONCLUSION: This comorbidity of two neurodegenerative diseases supports the ongoing discussion of a pathophysiological and clinical overlap of disease processes. Due to the potent pharmacological options for the IPS symptoms in these overlap syndromes, these patients should be offered optimal symptomatic dopaminergic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270441     DOI: 10.1159/000207795

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  7 in total

Review 1.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

2.  Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis.

Authors:  Marcello Deriu; Daniela Murgia; Alessandra Paribello; Emanuele Marcia; Maurizio Melis; Giovanni Cossu
Journal:  J Neurol       Date:  2011-04-23       Impact factor: 4.849

Review 3.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

4.  Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.

Authors:  Young-Min Lim; Hee Kyung Park; Jae Seung Kim; Chong Sik Lee; Sun Ju Chung; Jimin Kim; Kwang-Kuk Kim
Journal:  Neurol Sci       Date:  2012-06-28       Impact factor: 3.307

5.  ALS-Plus syndrome: non-pyramidal features in a large ALS cohort.

Authors:  Leo McCluskey; Shannon Vandriel; Lauren Elman; Vivianna M Van Deerlin; John Powers; Ashley Boller; Elisabeth McCarty Wood; John Woo; Corey T McMillan; Katya Rascovsky; Murray Grossman
Journal:  J Neurol Sci       Date:  2014-07-18       Impact factor: 3.181

6.  Parkinson's disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis.

Authors:  Panteha Fathinia; Andreas Hermann; Ulrike Reuner; Jan Kassubek; Alexander Storch; Albert C Ludolph
Journal:  J Neurol       Date:  2012-08-26       Impact factor: 4.849

7.  C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease.

Authors:  Karen Nuytemans; Güney Bademci; Martin M Kohli; Gary W Beecham; Liyong Wang; Juan I Young; Fatta Nahab; Eden R Martin; John R Gilbert; Michael Benatar; Jonathan L Haines; William K Scott; Stephan Züchner; Margaret A Pericak-Vance; Jeffery M Vance
Journal:  Ann Hum Genet       Date:  2013-07-12       Impact factor: 1.670

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.